GPNMB silencing suppresses the proliferation and metastasis of osteosarcoma cells by blocking the PI3K/Akt/mTOR signaling pathway

Jin,Rui; Jin,Ying‑Ying; Tang,Yi‑Lun; Yang,Hua‑Juan; Zhou,Xiao‑Qian; Lei,Zhe

doi:10.3892/or.2018.6346

GPNMB silencing suppresses the proliferation and metastasis of osteosarcoma cells by blocking the PI3K/Akt/mTOR signaling pathway

Authors:
- Rui Jin
- Ying‑Ying Jin
- Yi‑Lun Tang
- Hua‑Juan Yang
- Xiao‑Qian Zhou
- Zhe Lei
View Affiliations

Affiliations: Department of Medical Imaging, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China, Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China, Department of Orthopedics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China
Published online on: March 30, 2018 https://doi.org/10.3892/or.2018.6346
Pages: 3034-3040

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glycoprotein non‑metastatic melanoma protein B (GPNMB) is a glycoprotein that is highly expressed in various types of cancer, including osteosarcoma. However, its cellular functions and related mechanisms in osteosarcoma remain unclear. In the present study, a higher GPNMB mRNA level was observed in osteosarcoma tissues, than in adjacent non‑cancerous tissues. In addition, upregulation of the GPNMB mRNA and protein level was detected in the osteosarcoma cells SaOS2, 143B, MG63 and U2OS using western blot analysis and qPCR. Following transfection with GPNMB siRNA, the proliferation, migration and invasion of MG63 and U2OS cells were assessed using MTT and Transwell assays. The knockdown of GPNMB markedly inhibited the proliferation and metastasis of MG63 and U2OS cells. GPNMB silencing inhibited the activation of PI3K/Akt/mTOR signaling in MG63 and U2OS cells. PI3K/AKT activator insulin‑like growth factor‑1 (IGF‑1) significantly activated the PI3K/Akt/mTOR signaling and reversed the suppressive effects of GPNMB silencing. IGF‑1 counteracted the inhibitory effects of GPNMB silencing on the proliferation and metastasis of the MG63 and U2OS cells. In conclusion, we provided evidence that GPNMB silencing regulated the proliferation and metastasis of osteosarcoma cells by suppressing the PI3K/Akt/mTOR signaling pathway. Thus, GPNMB may be a potential therapeutic target for osteosarcoma treatment.

View Figures

View References

1	Vasquez L, Tarrillo F, Oscanoa M, Maza I, Geronimo J, Paredes G, Silva JM and Sialer L: Analysis of prognostic factors in high-grade osteosarcoma of the extremities in children: A 15-year single-institution experience. Front Oncol. 6:222016. View Article : Google Scholar : PubMed/NCBI
2	Gordon N and Kleinerman ES: Aerosol therapy for the treatment of osteosarcoma lung metastases: Targeting the Fas/FasL pathway and rationale for the use of gemcitabine. J Aerosol Med Pulm Drug Deliv. 23:189–196. 2010. View Article : Google Scholar : PubMed/NCBI
3	Ferguson WS and Goorin AM: Current treatment of osteosarcoma. Cancer Invest. 19:292–315. 2001. View Article : Google Scholar : PubMed/NCBI
4	Broadhead ML, Clark JC, Myers DE, Dass CR and Choong PF: The molecular pathogenesis of osteosarcoma: A review. Sarcoma. 2011:9592482011. View Article : Google Scholar : PubMed/NCBI
5	Safadi FF, Xu J, Smock SL, Rico MC, Owen TA and Popoff SN: Cloning and characterization of osteoactivin, a novel cDNA expressed in osteoblasts. J Cell Biochem. 84:12–26. 2001. View Article : Google Scholar : PubMed/NCBI
6	Maric G, Rose AA, Annis MG and Siegel PM: Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer. Onco Targets Ther. 6:839–852. 2013.PubMed/NCBI
7	Rose AA, Annis MG, Dong Z, Pepin F, Hallett M, Park M and Siegel PM: ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties. PLoS One. 5:e120932010. View Article : Google Scholar : PubMed/NCBI
8	Singh M, Del Carpio-Cano F, Belcher JY, Crawford K, Frara N, Owen TA, Popoff SN and Safadi FF: Functional roles of osteoactivin in normal and disease processes. Crit Rev Eukaryot Gene Expr. 20:341–357. 2010. View Article : Google Scholar : PubMed/NCBI
9	Rose AA and Siegel PM: Osteoactivin/HGFIN: Is it a tumor suppressor or mediator of metastasis in breast cancer? Breast Cancer Res. 9:4032007. View Article : Google Scholar : PubMed/NCBI
10	Maric G, Annis MG, Dong Z, Rose AA, Ng S, Perkins D, MacDonald PA, Ouellet V, Russo C and Siegel PM: GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin α5β1 for efficient breast cancer metastasis. Oncogene. 34:5494–5504. 2015. View Article : Google Scholar : PubMed/NCBI
11	Zhuo H and Zhou L: Gpnmb/osteoactivin: An indicator and therapeutic target in tumor and nontumorous lesions. Pharmazie. 71:555–561. 2016.PubMed/NCBI
12	Williams MD, Esmaeli B, Soheili A, Simantov R, Gombos DS, Bedikian AY and Hwu P: GPNMB expression in uveal melanoma: A potential for targeted therapy. Melanoma Res. 20:184–190. 2010.PubMed/NCBI
13	Fiorentini C, Bodei S, Bedussi F, Fragni M, Bonini SA, Simeone C, Zani D, Berruti A, Missale C, Memo M, et al: GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity. Exp Cell Res. 323:100–111. 2014. View Article : Google Scholar : PubMed/NCBI
14	Oyewumi MO, Manickavasagam D, Novak K, Wehrung D, Paulic N, Moussa FM, Sondag GR and Safadi FF: Osteoactivin (GPNMB) ectodomain protein promotes growth and invasive behavior of human lung cancer cells. Oncotarget. 7:13932–13944. 2016. View Article : Google Scholar : PubMed/NCBI
15	Halim A, Bagley RG and Keler T: Abstract 5032: Glycoprotein NMB (gpNMB) overexpression is prevalent in human cancers: Pancreatic cancer, non-small cell lung cancer, head and neck cancer, and osteosarcoma. Cancer Res. 76:5032. 2016. View Article : Google Scholar
16	Ludwig JA, Lamhamedi-Cherradi SE, Lee HY, Naing A and Benjamin R: Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance. Cancers. 3:3029–3054. 2011. View Article : Google Scholar : PubMed/NCBI
17	Ke M, Mo L, Li W, Zhang X, Li F and Yu H: Ubiquitin ligase SMURF1 functions as a prognostic marker and promotes growth and metastasis of clear cell renal cell carcinoma. FEBS Open Bio. 7:577–586. 2017. View Article : Google Scholar : PubMed/NCBI
18	Yuan TL and Cantley LC: PI3K pathway alterations in cancer: Variations on a theme. Oncogene. 27:5497–5510. 2008. View Article : Google Scholar : PubMed/NCBI
19	Liu Y, Bi T, Dai W, Wang G, Qian L, Shen G and Gao Q: Lupeol induces apoptosis and cell cycle arrest of human osteosarcoma cells through PI3K/AKT/mTOR pathway. Technol Cancer Res Treat. 15:NP16–NP24. 2016. View Article : Google Scholar : PubMed/NCBI
20	Ono Y, Tsuruma K, Takata M, Shimazawa M and Hara H: Glycoprotein nonmetastatic melanoma protein B extracellular fragment shows neuroprotective effects and activates the PI3K/Akt and MEK/ERK pathways via the Na⁺/K⁺-ATPase. Sci Rep. 6:232412016. View Article : Google Scholar : PubMed/NCBI
21	Zhu H, Wu Y, Zheng W and Lu S: CO-029 is overexpressed in gastric cancer and mediates the effects of EGF on gastric cancer cell proliferation and invasion. Int J Mol Med. 35:798–802. 2015. View Article : Google Scholar : PubMed/NCBI
22	Chen L, Wang Q, Wang GD, Wang HS, Huang Y, Liu XM and Cai XH: miR-16 inhibits cell proliferation by targeting IGF1R and the Raf1-MEK1/2-ERK1/2 pathway in osteosarcoma. FEBS Lett. 587:1366–1372. 2013. View Article : Google Scholar : PubMed/NCBI
23	Boniface K, Bernard FX, Garcia M, Gurney AL, Lecron JC and Morel F: IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol. 174:3695–3702. 2005. View Article : Google Scholar : PubMed/NCBI
24	Wang Y, Sun Y, Wu Y and Zhang J: Cucurbitacin E inhibits osteosarcoma cells proliferation and invasion through attenuation of PI3K/AKT/mTOR signaling. Biosci Rep: BSR20160165. 2016. View Article : Google Scholar
25	Hu K, Dai HB and Qiu ZL: mTOR signaling in osteosarcoma: Oncogenesis and therapeutic aspects (Review). Oncol Rep. 36:1219–1225. 2016. View Article : Google Scholar : PubMed/NCBI
26	Zhang XJ, Yu HY, Cai YJ and Ke M: Lycium barbarum polysaccharides inhibit proliferation and migration of bladder cancer cell lines BIU87 by suppressing Pi3K/AKT pathway. Oncotarget. 8:5936–5942. 2017.PubMed/NCBI
27	Kolb EA, Gorlick R, Billups CA, Hawthorne T, Kurmasheva RT, Houghton PJ and Smith MA: Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program. Pediatr Blood Cancer. 61:1816–1821. 2014. View Article : Google Scholar : PubMed/NCBI
28	Roth M, Barris DM, Piperdi S, Kuo V, Everts S, Geller D, Houghton P, Kolb EA, Hawthorne T, Gill J and Gorlick R: Targeting glycoprotein NMB with antibody-drug conjugate, glembatumumab vedotin, for the treatment of osteosarcoma. Pediatr Blood Cancer. 63:32–38. 2016. View Article : Google Scholar : PubMed/NCBI
29	Rose AA, Grosset AA, Dong Z, Russo C, Macdonald PA, Bertos NR, St-Pierre Y, Simantov R, Hallett M, Park M, et al: Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin Cancer Res. 16:2147–2156. 2010. View Article : Google Scholar : PubMed/NCBI
30	Torres C, Linares A, Alejandre MJ, Palomino-Morales R, Martin M, Delgado JR, Martinez J and Perales S: The potential role of the glycoprotein osteoactivin/glycoprotein nonmetastatic melanoma protein B in pancreatic cancer. Pancreas. 44:302–310. 2015. View Article : Google Scholar : PubMed/NCBI
31	Le B, Powers GL, Tam YT, Schumacher N, Malinowski RL, Steinke L, Kwon G and Marker PC: Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer. PloS One. 12:e01746582017. View Article : Google Scholar : PubMed/NCBI
32	Liu M, Bamodu OA, Huang WC, Zucha MA, Lin YK, Wu ATH, Huang CC, Lee WH, Yuan CC, Hsiao M, et al: 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway. Toxicol Appl Pharmacol. 325:48–60. 2017. View Article : Google Scholar : PubMed/NCBI
33	Rodon J, Dienstmann R, Serra V and Tabernero J: Development of PI3K inhibitors: Lessons learned from early clinical trials. Nat Rev Clin Oncol. 10:143–153. 2013. View Article : Google Scholar : PubMed/NCBI
34	Li X, Sun X, Wu J and Li Z: MicroRNA-613 suppresses proliferation, migration and invasion of osteosarcoma by targeting c-MET. Am J Cancer Res. 6:2869–2879. 2016.PubMed/NCBI
35	Song R, Tian K, Wang W and Wang L: P53 suppresses cell proliferation, metastasis, and angiogenesis of osteosarcoma through inhibition of the PI3K/AKT/mTOR pathway. Int J Surg. 20:80–87. 2015. View Article : Google Scholar : PubMed/NCBI
36	Keremu A, Maimaiti X, Aimaiti A, Yushan M, Alike Y, Yilihamu Y and Yusufu A: NRSN2 promotes osteosarcoma cell proliferation and growth through PI3K/Akt/MTOR and Wnt/β-catenin signaling. Am J Cancer Res. 7:565–573. 2017.PubMed/NCBI